menu
Home
Providing information you can trust, supporting the MS specialists you need

Questions about MS?

call:0800 032 38 39

or send us a message

Navigation

  • Home
  • Understanding MS
    • What is MS
      • About MS
      • Types of MS
      • Causes of MS
      • Facts and myths about MS
    • Diagnosing MS
      • Early signs of MS
      • Worried you have MS?
      • How is MS diagnosed?
      • Perspectives on diagnosis
    • Newly diagnosed with MS
      • What happens after MS diagnosis
      • Telling people
      • MS and your feelings
      • MS and life choices
      • Explaining MS to others
      • Newly diagnosed stories
    • MS symptoms and treatments
      • How is MS treated?
      • Symptoms
      • Treating MS symptoms
      • Managing relapses
      • Disease modifying drugs (MS Decisions)
      • Making the most of appointments
    • Living with MS
      • Taking charge of your MS
      • Living well with MS
      • MSTV: Young people and MS
      • Family and relationships
      • Financial and legal issues
      • Home and travel
      • Working and studying with MS
      • Map of MS services
  • News
    • News about MS

      Latest news on MS treatments, research and specialist services

    • MS Trust news

      News about the MS Trust and its activities

    • Views and comment

      Perspectives on hot topics in the world of MS

    • MS in the media

      Our weekly roundup of the latest MS news stories

    • Open Door

      Our free, quarterly newsletter for people affected by MS

  • Research
    • Research and MS
    • Drugs in development
    • Research updates
    • Getting involved in research
    • Research funded by the MS Trust
  • Health professionals
    • MS Trust Projects
      • Advanced MS Champions programme
      • Specialist Nurse Programme
      • MS Forward View
      • Generating Evidence in MS Services (GEMSS)
    • Resources
      • Sharing ideas in MS services
      • Evidence and evaluation
      • Practical guides and useful links
      • Developing relapse services
      • MS in Practice
      • Health Professional Blog
    • Professional development
      • MS Trust conference
      • Foundation training
      • Funding your learning
      • QuDoS in MS awards
      • Student nurses
    • Therapists in MS (TiMS)
      • About TiMS
      • TiMS news and newsletter
      • Courses
      • Podcasts and presentations
      • AHP competency framework
      • MS competency framework
      • Current clinical research trials
      • How to conduct research
      • Outcome measures
  • Get involved
    • Donate
      • Donate now
      • Ways to donate
      • How your donations help
      • Support our appeal
      • Play our lottery
      • Leave a gift in your will
      • Donate in memory
      • Charitable trusts and foundations
      • Corporate giving
    • Fundraise
      • Why support us
      • Fundraise your way
      • A-Z of ideas
      • Top 10 tips
      • How we can help you
      • Supporter hall of fame
      • Be Bold in Blue
    • Take part in an event
      • Running events
      • Cycling events
      • UK events
      • Adventure challenges
      • Skydive for the MS Trust
      • Miles for MS
    • Volunteer
      • Help in a Christmas card shop
      • Local fundraising groups
    • Shop
      • Merchandise
      • MS Trust clothing
      • Order a publication
      • Raise money while you shop online
    • MS Awareness Week 2018
  • About us
    • Who we are
      • Meet the team
      • Meet the trustees
      • Where we came from
    • What we do
      • Supporting people with MS
      • Supporting specialist services
      • Influencing health policy
    • How we spend our funds
      • Annual review
      • Annual report and accounts
    • How you can help us
      • Make a donation
      • Get involved in fundraising
    • Open Door
      • Read the latest Open Door
      • Sign-up for Open Door
      • Read previous issues of Open Door

Utility Navigation

  • Order a publication
  • Map of MS services
  • Keep in touch
  • A-Z
  • A-Z of MS
  • Donate
  • Search

You are here

  • Home
  • News
  • News about MS

Ocrelizumab (Ocrevus) gets European licence for relapsing and primary progressive MS

11 January 2018

The European Commission has granted marketing authorization for ocrelizumab (Ocrevus) for the treatment of both active relapsing MS and early active primary progressive multiple sclerosis. This follows a recommendation from the European Medicines Agency in November that a licence should be granted.

  • Active relapsing MS means people who are having relapses or showing new lesions on MRI scans
  • Early primary progressive MS is defined as people who have had symptoms of MS for 15 years or less, have an EDSS of 3.0 to 6.5 and evidence of MS activity on MRI scans

This is exciting news, especially for people with progressive MS as ocrelizumab is the first drug to be licensed for primary progressive MS in Europe.  We hope that the availability of a new treatment will lead to a renewed focus on the needs of all people with progressive MS and improve their access to services.

Jo Sopala, Director of Development 

Ocrelizumab will now need to be appraised by NICE and the SMC to determine NHS availability in the UK. NICE has started the process and the MS Trust is contributing to the appraisal. A decision from NICE for relapsing MS is expected to be published in July 2018, with the drug potentially available on the NHS in England and Wales three months later.  A decision from NICE for primary progressive MS is expected to be published later in 2018.  

About ocrelizumab

Ocrelizumab is taken as an intravenous infusion (drip). The first dose is given as two separate infusions, two weeks apart. Further doses are given as one infusion every six months.

In clinical trials for relapsing MS, ocrelizumab reduced the risk of relapses by 50% compared to beta interferon (Rebif), reduced disability progression and the number of lesions seen on MRI scans.

For primary progressive MS, people taking ocrelizumab were 24% less likely to experience increased disability compared to those taking placebo.

Across all the clinical trials, infusion-related reactions, chest infections and herpes (oral herpes and shingles) were more frequent in those taking ocrelizumab.

Find out more

  • Ocrelizumab (Ocrevus)
  • Roche press release
  • NICE - appraisal for ocrelizumab for relapsing MS
  • NICE - appraisal for primary progressive MS
  • Drugs in development

Sign_up_for_MS_Trust_news.png

  • April 2018 (1)
  • March 2018 (3)
  • February 2018 (1)
  • January 2018 (5)
  • December 2017 (1)
  • November 2017 (3)
  • October 2017 (2)
  • September 2017 (1)
  • August 2017 (1)
  • July 2017 (1)
  • June 2017 (2)
  • May 2017 (2)
  • April 2017 (3)
  • March 2017 (5)
  • February 2017 (2)
  • December 2016 (3)
  • November 2016 (5)
  • October 2016 (3)
  • September 2016 (2)
  • August 2016 (3)
  • July 2016 (2)
  • June 2016 (6)
  • May 2016 (3)
  • April 2016 (2)
  • March 2016 (4)
  • February 2016 (4)
  • January 2016 (3)
  • December 2015 (3)
  • November 2015 (4)
  • October 2015 (3)
  • September 2015 (3)
  • August 2015 (4)
  • June 2015 (1)
  • April 2015 (2)
  • March 2015 (2)
  • January 2015 (4)
  • December 2014 (2)
  • November 2014 (1)
  • October 2014 (6)
  • September 2014 (3)
  • August 2014 (5)
  • July 2014 (2)
  • June 2014 (4)
  • April 2014 (4)
  • March 2014 (1)
  • January 2014 (1)
  • November 2013 (2)
  • October 2013 (2)
  • December 2012 (1)
  • June 2012 (1)
  • May 2012 (1)
  • February 2010 (1)

Site Map

  • Donate
  • Work for us
  • Contact us
  • Accessibility
  • Privacy policies
  • About us

Connect with us

  • Facebook
  • Twitter
  • YouTube

Smallprint

Multiple Sclerosis Trust

Spirella Building, Bridge Road, Letchworth Garden City, Hertfordshire, SG6 4ET

Call 01462 476700

info@mstrust.org.uk

charity number: 1088353

Registered as a limited company in England and Wales 4247766

Affiliates Menu

  • Fundraising Standards Board
  • Health and Care Information